Aurobindo Pharma Limited (India), a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients announced the signing of a definitive agreement to acquire from Apotex International, its commercial operations and certain supporting infrastructure in five European countries.
Closing of the transaction is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. The acquisition is in line with Aurobindo’s strategy to strengthen and grow its European business and to expand in Eastern Europe.
In Poland, Aurobindo will add significant sales based on the established brand name “APO” as well as a dedicated sales force covering physicians and the pharmacy network. In Poland and the Czech Republic, Aurobindo will become one of top 15 generics companies in each country.
In the Netherlands, the acquisition will lead to Aurobindo becoming a leading OTC company by volume, in Spain it will strengthen the company’s position in the generics market and in Belgium, the acquisition will provide Aurobindo with an entry into the retail generics space, where it will become a top 5 player.
Aurobindo expects to acquire commercial infrastructure including experienced personnel, products, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium. The acquisition includes a portfolio of over 200 prescription drugs and 88 OTC products and an additional pipeline of over 20 products which are expected to be launched over the next two years.
Aurobindo and Apotex will enter into a transitional manufacturing and supply arrangement to support the ongoing growth plans of these businesses.
Aurobindo has been expanding its European footprint since 2006 both organically and via carefully selected acquisitions across several key markets, most notably in 2014 with the acquisition of Actavis’s commercial operations in seven Western European countries and in 2017 with the acquisition of Generis Farmaceutica in Portugal.
Aurobindo currently has a presence in nine European countries, Portugal, France, Germany, the Netherlands, Spain, Italy, Belgium, UK and Romania. Its current European business spans the generics, tender generics, branded generics and hospital generics segments supported by an established commercial and hospital sales infrastructure. In the fiscal year ended March 2018, Aurobindo had sales in Europe of €577 million.
Aurobindo plans to leverage the infrastructure of the acquired businesses to strengthen its commercial reach in a number of countries and synergies will result from Aurobindo optimizing the potential of its vertically integrated platform.
Aurobindo’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics. The US and Europe are Aurobindo’s two most important markets accounting for over 70% of the company’s $ 2.6 billion sales. The company’s manufacturing facilities are approved by the world’s leading regulatory agencies including US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. Aurobindo is headquartered in Hyderabad, India.